van Gelder T - Search Results

1

Randomized trial to evaluate the use of increasing the steroid dose during conversion from cyclosporine to azathioprine.

Roodnat JI, Zietse R, Rischen-Vos J, van Gelder T, IJzermans JN, Weimar W. Roodnat JI, et al. Among authors: van gelder t. Transplant Proc. 1998 Jun;30(4):1199-200. doi: 10.1016/s0041-1345(98)00208-5. Transplant Proc. 1998. PMID: 9636486 Clinical Trial. No abstract available.

2

Reversal of graft rejection with monoclonal anti-interleukin-2 receptor.

van Gelder T, Balk AH, Mochtar B, Weimar W. van Gelder T, et al. Lancet. 1992 Apr 4;339(8797):873. doi: 10.1016/0140-6736(92)90318-w. Lancet. 1992. PMID: 1347884 No abstract available.

3

Successful treatment of Kaposi's sarcoma in a renal allograft recipient.

Marsman WA, Van Gelder T, Mulder AH, Ijzermans JN, Zietse R, Weimar W. Marsman WA, et al. Among authors: van gelder t. Nephrol Dial Transplant. 1995;10(6):900-1. Nephrol Dial Transplant. 1995. PMID: 7566628 No abstract available.

4

A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.

van Gelder T, Zietse R, Mulder AH, Yzermans JN, Hesse CJ, Vaessen LM, Weimar W. van Gelder T, et al. Transplantation. 1995 Aug 15;60(3):248-52. doi: 10.1097/00007890-199508000-00007. Transplantation. 1995. PMID: 7645037 Clinical Trial.

5

Epstein-Barr virus in smooth-muscle tumors.

van Gelder T, Vuzevski VD, Weimar W. van Gelder T, et al. N Engl J Med. 1995 Jun 22;332(25):1719. doi: 10.1056/nejm199506223322516. N Engl J Med. 1995. PMID: 7760881 No abstract available.

6

Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.

van Gelder T, Mulder AH, Balk AH, Mochtar B, Hesse CJ, Baan CC, Vaessen LM, Weimar W. van Gelder T, et al. J Heart Lung Transplant. 1995 Mar-Apr;14(2):346-50. J Heart Lung Transplant. 1995. PMID: 7779855 Clinical Trial.

7

Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.

van Gelder T, Knoop CJ, Hesse CJ, Vaessen LM, Balk AH, Yzermans JN, Weimar W. van Gelder T, et al. Transplant Proc. 1995 Feb;27(1):856-8. Transplant Proc. 1995. PMID: 7879206 Clinical Trial. No abstract available.

8

van Gelder T, Kroes LC, Mulder A, Gratama JW, Weimar W. van Gelder T, et al. Transplantation. 1994 Oct 15;58(7):852-5. Transplantation. 1994. PMID: 7940722 No abstract available.

9

Cortical blindness due to cyclosporin.

Van Leeuwen ML, Van Gelder T, Van Gemert HM, Weimar W. Van Leeuwen ML, et al. Among authors: van gemert hm, van gelder t. Neth J Med. 1993 Aug;43(1-2):69-70. Neth J Med. 1993. PMID: 8232697

10

Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.

Hesse CJ, van Gelder T, Vaessen LM, Knoop CJ, Balk AH, Yzermans JN, Jutte NH, Weimar W. Hesse CJ, et al. Among authors: van gelder t. Immunopharmacology. 1995 Sep;30(3):237-46. doi: 10.1016/0162-3109(95)00028-r. Immunopharmacology. 1995. PMID: 8557524 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

483 results

Search Page

Filters